Publikationsdatenbank

Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza (2008)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Rosas, Cristina

Van de Walle, Gerlinde R

Metzger, Stephan M

Hoelzer, Karin

Dubovi, Edward J

Kim, Sung G

Parrish, Colin R

Osterrieder, Nikolaus

Quelle

Vaccine

Bandzählung: 26

Heftzählung: 19

Seiten: 2335 – 2343

ISSN: 0264-410x

Sprache

Englisch

Verweise

DOI: 10.1016/j.vaccine.2008.02.064

Pubmed: 18407383

Kontakt

Institut für Virologie

Robert-von-Ostertag-Str. 7-13
14163 Berlin
+49 30 838 51833
virologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

In 2004, canine influenza virus (CIV) was identified as a respiratory pathogen of dogs for the first time and found to be closely related to H3N8 equine influenza virus (EIV). We generated a recombinant vectored vaccine that expresses H3 of a recent isolate of EIV using equine herpesvirus type 1 (EHV-1) as the delivery vehicle. This EHV-1 vectored vaccine exhibited robust and stable EIV H3 expression and induced a strong influenza virus-specific response in both mice and dogs upon intranasal or subcutaneous administration. Furthermore, upon challenge with the recent CIV isolate A/canine/PA/10915-07, protection of vaccinated dogs could be demonstrated by a significant reduction in clinical sings, and, more importantly, by a significant reduction in virus shedding. We concluded that the EHV-1/H3 recombinant vector can be a valuable alternative for protection of dogs against clinical disease induced by CIV and can significantly reduce virus spread.